NextCure, Inc.
NASDAQ · us_market
No AI insight generated yet for this ticker.
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells; NC181 a humanized antibody targeting ApoE4 for the treatment of Alzheimer's disease; and NC605 an antibody that targets Siglec-15, as well as chronic bone diseases, such as osteoarthritis and non-union fractures. The company also develop SIM0505, a novel antibody-drug conjugate (ADC) targeting CDH6 (cadherin-6 or K-cadherin) for the treatment of solid tumors. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| RenTech | quant | 60.5K | $646.50K | 0.00% | Added+80.0% | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-05-07 | -2.03 | -1.87 | +7.88% |
| 2026-03-05 | -2.42 | -0.81 | +66.48% |
| 2025-11-05 | -3.98 | -3.22 | +19.16% |
| 2025-08-07 | -4.61 | -11.29 | -144.64% |
| 2025-05-01 | -4.80 | -4.68 | +2.50% |
| 2025-03-06 | -4.32 | -4.92 | -13.89% |
| 2024-11-07 | -3.84 | -4.92 | -28.12% |
| 2024-08-01 | -4.95 | -6.60 | -33.33% |
| 2024-05-02 | -5.52 | -6.26 | -13.48% |
| 2024-03-21 | -6.52 | -6.24 | +4.29% |
| 2023-11-02 | -7.84 | -6.12 | +21.94% |
| 2023-08-03 | -7.20 | -7.68 | -6.67% |
| 2023-05-04 | -7.44 | -6.96 | +6.45% |
| 2023-03-02 | -7.88 | -7.44 | +5.58% |
| 2022-11-03 | -7.80 | -8.16 | -4.62% |
| 2022-08-04 | -9.02 | -7.80 | +13.56% |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| NXTC | -33.76% | -48.55% | -56.31% | +5.01% |
| XLV | +2.97% | -4.64% | -3.44% | +12.69% |
| Alpha (stock − sector) | -36.73% | -43.91% | -52.86% | -7.67% |